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Soft tissue tumors of infancy encompass an overlapping spectrum of diseases that pose
unique diagnostic and clinical challenges. We studied genomes and transcriptomes of
cryptogenic congenital mesoblastic nephroma (CMN), and extended our findings to five
anatomically or histologically related soft tissue tumors: infantile fibrosarcoma (IFS),
nephroblastomatosis, Wilms tumor, malignant rhabdoid tumor, and clear cell sarcoma of the
kidney. A key finding is recurrent mutation of EGFR in CMN by internal tandem duplication of
the kinase domain, thus delineating CMN from other childhood renal tumors. Furthermore,
we identify BRAF intragenic rearrangements in CMN and IFS. Collectively these findings
reveal novel diagnostic markers and therapeutic strategies and highlight a prominent role of
isolated intragenic rearrangements as drivers of infant tumors.
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Many childhood tumors show a predilection for specificdevelopmental stages. Tumors that predominantlyoccur in infancy include congenital mesoblastic
nephroma (CMN), which accounts for 4% of all childhood renal
malignancies and the majority of those diagnosed in children
under 6 months of age1,2. CMN is classified histologically into
classical, cellular, and mixed subtypes based primarily on degree
of cellularity and mitotic activity3. The cellular variant is char-
acterized by a sarcoma-like diffuse hypercellular morphology,
whereas classical CMN is composed of less proliferative spindle
cells3. Cellular CMN is driven by rearrangements involving the
tropomyosin receptor kinase (TRK) gene NTRK3, most com-
monly a t(12;15)(p13;q25) reciprocal translocation with the ETV6
transcription factor4,5. Less frequent somatic aberrations include
trisomies of chromosomes 8, 11, 17, and 206,7 and rarer TRK
fusions, involving NTRK1, NTRK2, or NTRK38. By contrast, the
genetic changes underpinning the classical variant, accounting for
>30% of cases, are unknown9. Cellular CMN shares its genetic
and morphological hallmarks with infantile fibrosarcoma (IFS), a
spindle cell tumor typically arising in the soft tissues of the
extremities or abdomen5,9,10.
Standard treatment for CMN and IFS is complete surgical
resection9–11. In the case of IFS, local control frequently requires
cytotoxic chemotherapy10,11. The role for up-front chemotherapy
in CMN is less clear9. Recently, a phase I/II clinical trial of a
selective TRK inhibitor, larotrectinib, reported high response
rates in diverse tumor types harboring TRK gene fusions,
including IFS and other soft tissue tumors of infancy12. Morbidity
and infrequent death result from tumor recurrence or from
treatment-related complications9–11.
Here, we investigated the genetic basis of CMN and IFS
lacking the canonical NTRK3-ETV6 fusion gene. We identify
oncogenic rearrangements in MAPK signaling genes across all
cases interrogated by unbiased sequencing, notably ther-
apeutically tractable intragenic rearrangements in EGFR and
BRAF.
Results
Overview of the genomic landscape of CMN. To identify the
genetic basis of cryptogenic CMN, we first applied whole genome
and transcriptome sequencing to a discovery cohort of ten clas-
sical CMN lacking an NTRK3 fusion (Supplementary Data 1).
Somatic variants were identified by comparing tumor and mat-
ched peripheral blood sequences (see Methods). The genomic
landscape was universally quiet, with a low burden of point
mutations (median of 45 substitutions and 9 insertions or dele-
tions per genome; Supplementary Data 2). The predominant
mutational signatures, as defined by the trinucleotide context of
substitutions, were the ubiquitous signatures 1 and 513
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Fig. 1 EGFR internal tandem duplication. a The genomic footprint of EGFR is depicted with exons represented by gray and green vertical lines. Green exons
encode the kinase domain. Blue lines superiorly show the tandem duplications found in the discovery cohort of ten congenital mesoblastic nephroma of
classical histology. b Schematic of the wild-type transcript. c Schematic of the fusion transcript annotated with cDNA sequence of rearrangements (sense
orientation) and protein translation. d Intragenic copy number of EGFR showing focal amplification over the kinase domain (x-axis: genomic coordinate;
y-axis: copy number derived from coverage). e Representative phospo-ERK immunohistochemistry
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(Supplementary Fig. 1). Copy number changes and structural
rearrangements were likewise scarce (Supplementary Fig. 2).
Internal tandem duplication of the EGFR kinase domain in
CMN. Annotating all cases for potential oncogenic variants
revealed a single intragenic, in-frame internal tandem duplication
(ITD) of the EGFR kinase domain in all ten tumors (Table 1;
Fig. 1; Supplementary Data 3). The breakpoints clustered in a
narrow genomic window around the kinase domain of EGFR
encoded in exons 18−25 (Fig. 1a). This rearrangement is rarely
observed in several other tumor types including in glioma and in
lung adenocarcinoma, and confers sensitivity to a targeted EGFR
inhibitor, afatinib14. We validated all rearrangements by genomic
copy number analysis and reconstruction of cDNA reads span-
ning the breakpoint junction (Fig. 1; see Methods). Of note, the
same mutant cDNA junction sequence was found in every case,
irrespective of the genomic location of breakpoints. A search for
additional known or novel driver variants revealed no further
plausible candidates in any of the EGFR-mutant tumors. We next
extended this investigation to seven non-classical CMN lacking
an NTRK3 fusion, including four mixed cellularity cases and three
cellular tumors (Table 1; Supplementary Data 1). Two of the four
mixed cellularity tumors surveyed also harbored an EGFR-ITD.
Of note, for one child with EGFR-ITD-positive mixed cellularity
CMN (PD37214), both primary tumor and recurrence were
studied, with no additional driver events apparent at relapse.
BRAF rearrangements in CMN and IFS. A further striking
finding was the discovery of mutations in the BRAF oncogene in 2/3
cellular histology CMNs. BRAF fusions have been implicated in a
minority of IFS but not in CMN15. In both cases the BRAF
rearrangement involved a compound deletion of conserved region 1
(CR1) and tandem duplication of exon 2 (Fig. 2; Table 1; Supple-
mentary Data 3). CR1 encompasses the negative regulatory Ras-
binding domain (RBD), loss of which is predicted to generate a
constitutively active form of BRAF16,17. Mutated tumors displayed
intense staining of phosphorylated ERK by immunohistochemistry,
consistent with activated signaling downstream of BRAF
(Figs. 1e and 2e). A further tumor harbored the KIAA1549-BRAF
fusion, a molecular hallmark of a childhood brain tumor, pilocytic
astrocytoma18,19. This fusion likewise results in loss of the N-
terminal portion of the BRAF protein containing the RBD17,18.
Other TRK fusions in CMN. The remaining two cases of CMN
interrogated by whole genome and transcriptome sequencing
were accounted for by gene fusions involving NTRK1, an alter-
nate kinase of the TRK family of protein kinases: TPR-NTRK1
and LMNA-NTRK1. Both of these fusions have been observed in
IFS and rarely in adult cancers, but not, to our knowledge, in
CMN20–23 (Table 1). Hence, every cryptogenic CMN interrogated
by whole-genome sequencing contained an oncogenic rearran-
gement in BRAF, EGFR, or NTRK1, all of which encode kinases
involved in MAPK signaling and are amenable to inhibition with
existing drugs9,12,14,17,24.
EGFR-ITD distinguishes CMN from other childhood renal
tumors. To validate and extend our findings, we screened IFS and
a range of childhood renal tumors for EGFR-ITD, BRAF-ID, and
ETV6-NTRK3 using PCR. Tumor types included additional cases
of CMN (n= 63), IFS (n= 26), Wilms tumor (n= 208), clear cell
sarcoma of the kidney without BCOR rearrangements (n= 20),
malignant rhabdoid tumor (n= 3), and nephroblastomatosis
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Fig. 2 Internal BRAF deletion. a The genomic footprint of BRAF is depicted with exons represented by gray, green, and orange vertical lines. Green and
orange exons encode the kinase domain and conserved region 1, respectively. Horizontal lines above exons demarcate rearrangements (blue: tandem
duplication; red: deletion). b Outline of wild-type transcript. c Outline of fusion transcript with cDNA sequence of rearrangements (sense orientation) with
translation. d Intragenic copy number of BRAF (x-axis: genomic coordinate; y-axis: copy number derived from coverage). e Representative phospho-ERK
immunohistochemistry
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(n= 12; Table 1; Supplementary Data 1). EGFR-ITD was most
prevalent in classical and mixed cellularity CMN, though was also
found in cellular CMN (2/17 cases). The frequency of EGFR
rearrangement in classical tumors was lower in the validation
cohort (20/35 cases) than in the initial discovery cohort (10/10
cases). None of the IFS cases, nor other childhood kidney tumors,
harbored EGFR-ITD. However, we encountered three cases of IFS
with intragenic BRAF deletions. Remarkably, in two cases BRAF-
ID co-occurred with NTRK3 fusions, the disease-defining muta-
tion of IFS. We were unable to accurately estimate relative allele
frequencies by nested PCR (see Methods). Hence, it is possible
that both fusions co-exist within the same clone or represent
independent clones that evolved in parallel within the same tumor.
Discussion
In this exploration of infant tumors we identify ITD of the EGFR
kinase domain that delineates a genetic subgroup of CMN
transcending histological subtypes. Additionally, we report a
novel rearrangement of BRAF present in both cellular CMN and
IFS. These mutations represent diagnostic markers that can be
readily integrated into routine clinical practice. Furthermore,
EGFR and BRAF emerge as therapeutic targets, which may be
exploited in certain clinical situations, e.g., large surgically
intractable tumors, disease recurrence or metastases.
It is noteworthy that an oncogenic mutation was identified in
every tumor that we studied by whole-genome sequencing. Of
these, 78% harbored either EGFR-ITD or BRAF-ID, while the
remaining 22% presented with non-canonical mutations invol-
ving BRAF, NTRK1, or NTRK3. This suggests that less recurrent
rearrangement variants, albeit implicated in the same signaling
circuity, may elude detection by targeted diagnostic assays.
Moreover, our results indicate that a subset of tumors harbor
multiple drivers with important implications for targeted therapy
efforts. The finding of co-mutation of NTRK3 and BRAF in IFS
raises the possibility of intrinsic resistance of some tumors to
TRK inhibition, regardless of whether these mutations occur in
the same clone or in independent competing clones. This finding
is pertinent to clinical trials of TRK inhibitors in CMN and IFS12.
In this vein a structurally similar BRAF fusion transcript, albeit
without duplication of exon 2, has recently been implicated as a
mechanism of resistance to certain BRAF/MEK inhibitors16,17.
These considerations underscore the need for adequate genomic
profiling in order to match patients to the most appropriate
basket studies and to enable meaningful interpretation of
treatment responses. Therefore, we would advocate extending the
diagnostic work-up of refractory or relapsed CMN and IFS to
whole genome sequencing, particularly in the context of clinical
trials.
Biologically our findings draw further parallels between CMN
and IFS. We identify BRAF and NTRK1 as additional cancer
genes operative in both malignancies, substantiating the view that
these diagnoses represent variants on the same disease spectrum
converging on aberrant RAS-RAF-MEK-ERK signaling5,8,9.
Furthermore, in the wider context of the childhood cancer
genome, our findings add to the growing body of studies that
identify short distance intragenic rearrangements as a dominant
source of oncogenic mutations in otherwise quiet genomes.
We note the parallel between CMN, clear cell sarcoma of
the kidney and low-grade glioma that are in large part driven
by ITDs often involving kinase domains, mostly as isolated
driver events18,25–29. Furthermore, even in acute myeloid
leukemia, where FLT3-ITD is a recurrent driver event in
adult disease, childhood AML demonstrates a distinct structural
variant profile enriched for focal chromosomal gains and
losses30. We can only speculate on the biological significance
of this parallel which may allude to specific mutational
mechanisms operative during discrete stages of human
development.
Methods
Patient samples. All tissue samples were obtained after gaining written informed
consent for tumor banking and future research from the patient (or their guardian)
in accordance with the Declaration of Helsinki and appropriate national and local
ethical review processes. German tissue samples were obtained from the following
studies: SIOP93-01/GPOH and SIOP2001/GPOH (Ethikkommission der
Ärztekammer des Saarlandes reference numbers 23.4.93/Ls and 136/01), the
PTT2.0 study (Medical Faculty Heidelberg ethics reference number S-546/2016),
the CWS trials CWS-96 and CWS-2002P (Universitätsklinikum Tübingen Medi-
zinische Fakultät ethics approval, reference numbers 105/95 and 51/2003) and the
SoTiSaR registry (ethics approval reference 158/2009B02). UK patients were
enrolled under ethics approval from National Research Ethics Service Committee
East of England, Cambridge Central (reference 16/EE/0394). Use of UK archival
material was approved by the National Research Ethics Service Committee London
Brent (reference 16/LO/0960). Additional tissue was obtained from the UK Chil-
dren’s Cancer and Leukaemia Group tissue bank.
Sequencing. Tumor DNA and RNA were extracted from fresh frozen tissue that
had been reviewed by reference pathologists. Normal tissue DNA was derived from
blood samples. Whole genome sequencing was performed by 150-bp paired-end
sequencing on the Illumina HiSeq X platform. We followed the Illumina no-PCR
library protocol to construct short insert libraries, prepare flowcells, and generate
clusters. Coverage was at least 30×. Messenger RNA was enriched by polyA-
Table 1 Rearrangements in infant soft tissue tumors
Assay Tumor
type
Subtype Total EGFR-ITD BRAF-ID BRAF-ID+
ETV6-
NTRK3
ETV6-
NTRK3
KIAA1549-
BRAF
LMNA-
NTRK1
EML4-
NTRK3
TPR-
NTRK1
WGS+mRNA
sequencing
CMN Cellular 3 0 2 0 0 0 1 0 0
Classical 10 10 0 0 0 0 0 0 0
Mixed 4 2 0 0 0 1 0 0 1
IFS − 1 0 0 0 0 0 0 1 0
PCR for EGFR-ITD,
BRAF-ID and ETV6-
NTRK3
CMN Cellular 17 2 0 0 13 – – – –
Classical 35 20 0 0 0 – – – –
Mixed 11 9 0 0 0 – – – –
IFS – 26 0 1 2 16 – – – –
WT – 208 0 0 0 0 – – – –
CCSKa – 20 0 0 0 0 – – – –
MRT – 3 0 0 0 0 – – – –
NB – 12 0 0 0 0 – – – –
CMN congenital mesoblastic nephroma, IFS infantile fibrosarcoma,WTWilms tumor, CCSK clear cell sarcoma of the kidney,MRTmalignant rhabdoid tumor, NB nephroblastomatosis,WGS whole genome
sequencing, mRNA messenger RNA, PCR polymerase chain reaction
aNegative for BCOR rearrangement
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selection and sequenced on an Illumina HiSeq 2000 (paired end, 75-bp read
length). DNA and RNA sequencing reads were aligned to the GRCh 37d5 reference
genome using the Burrows−Wheeler transform (BWA-MEM)31 and STAR
(2.0.42)32, respectively.
Variant detection. The Cancer Genome Project (Wellcome Trust Sanger Institute)
variant calling pipeline was used to call somatic mutation and includes the fol-
lowing algorithms: CaVEMan (1.11.0)33 for substitutions, an in-house version of
Pindel (2.2.2; github.com/cancerit/cgpPindel)34 for indels, BRASS (5.3.3; github.
com/cancerit/BRASS) for rearrangements, and ASCAT NGS (4.0.0) for copy
number aberrations35. RNA sequences were analyzed with an in-house pipeline
(github.com/cancerit/cgpRna/wiki) which uses HTSeq36 for gene feature counts,
and a combination of TopHat-Fusion (v2.1.0)37, STAR-fusion (v0.1.1)32 and
DeFuse (v0.7.0)38 to detect expressed gene fusions. In addition to filters inherent to
the CaVEMan algorithm, we used the following post-processing filtering criteria
for substitutions: a minimum of two reads in each direction reporting the mutant
allele, at least tenfold coverage at the mutant allele locus, minimum variant allele
fraction 5%; no insertion or deletion called within a read length (150 bp) of the
putative substitution, no soft-clipped reads reporting the mutant allele, and a
median BWA alignment score of the reads reporting the mutant allele ≥140. The
following variants were flagged for additional inspection for potential artifacts,
germline contamination or index-jumping event: any mutant allele reported within
150 bp of another variant, any mutant allele with a population allele frequency >1
in 1000 according to any of five large polymorphism databases (ExAC, 1000
Genomes Project, ESP6500, CG46, Kaviar), variant reported in more than 10% of
the tumor samples and mutant allele reported in >1% of the matched normal reads.
For indels, the inbuilt filters of the Pindel algorithm, as implemented in our
pipeline, were used. In addition, recurrent indels occurring in >2 samples were
flagged for additional inspection.
Mutational signatures were derived using principal component analysis and
non-negative matrix factorization as implemented in the SomaticSignatures
R package39.
Variant validation. The Cancer Genome Project (Wellcome Trust Sanger Insti-
tute) variant calling pipeline has been continually validated and bench-marked40,41.
We confirmed variant calling quality through manual visual inspection of raw
sequencing read for 8% of all variants called. All rearrangements reported were
validated by reconstruction at base pair resolution and by cDNA reads spanning
the breakpoint junction.
Analysis of mutations in cancer genes. We considered variants as potential
drivers if they presented in established cancer genes42. Tumor suppressor coding
variants were considered if they were annotated as functionally deleterious by an
in-house version of VAGrENT (http://cancerit.github.io/VAGrENT/)43 or were
disruptive rearrangement breakpoints or focal (<1Mb) homozygous deletions.
Mutations in oncogenes were considered driver events if they were located at
previously reported canonical hot spots (point mutations) or amplified the intact
gene. Amplifications also had to be focal (<1Mb) and increase the copy number of
oncogenes to a minimum of five copies for a diploid genome. To search for driver
variants in novel cancer genes or in non-coding regions, we employed previously
developed statistical methods that identify significant enrichment of mutations,
taking into account various confounders such as overall mutation burden and local
variation in the mutability of the genomic region44.
Targeted mutation screening. RNA from frozen tumors (1 µg) or corresponding
to approximately 5 cm2 of 10 µm FFPE sections was reverse transcribed using
oligo-dT or random hexamer primers (RevertAid first strand cDNA synthesis kit,
ThermoFisher). PCR screening was performed using primer combinations that
allow amplification of candidate alterations as well as additional control fragments
from the unaffected allele to assess cDNA quality. Amplified fragments were
sequenced by Sanger sequencing (GATC, Konstanz, Germany) using primers
detailed in Supplementary Table 1.
Immunohistochemistry. Immunohistochemical staining for phospho-ERK1/2
(Cell Signaling Technology, clone D13.14.4E) was performed according to standard
protocol (dilution 1:800, pre-treatment with target retrieval TR6.1, Dako). Results
were scored in a semi-quantitative fashion (negative, weak, moderate, strong).
Code availability. The algorithms used to analyze sequencing data are available at
http://cancerit.github.io/.
Data availability. All data supporting the findings of this study are available within
the article and its supplementary files or from the corresponding author on rea-
sonable request. Sequencing data have been deposited at the European Genome-
Phenome Archive (http://www.ebi.ac.uk/ega/) that is hosted by the European
Bioinformatics Institute (accession numbers EGAS00001002534 and
EGAS00001002171).
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